Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Educational video boosts prostate cancer screening intentions in men

As part of a comprehensive effort to improve cancer screenings among diverse communities, Penn Medicine’s Abramson Cancer Center (ACC) Community Outreach and Engagement team developed

April 10, 2024

At BIO, signs Congress’ tough stance on China is chilling biotech relationships

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a

June 6, 2024

8-Hour Eating Window Improved Glycemic Control, Small Study Shows

Eating within an 8-hour window improved glycemic variability in adults at risk for type 2 diabetes, an interim analysis of a randomized crossover study of

September 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.